Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best doses of buparlisib, gemcitabine
hydrochloride, and cisplatin in treating patients with solid tumors that have spread to other
places in the body. Buparlisib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride
and cisplatin, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Giving buparlisib, gemcitabine hydrochloride,
and cisplatin may be a better treatment for solid tumors.